

10. The method according to claim 9, wherein a class-I positive cancer cell is present.

11. The method according to claim 9 or 10, wherein said cancer cells are deficient for or have lower levels of class I antigen expression.

12. The method according to claim 9 or 10, wherein said cancer cells express B7, or a combination of B7 and a cancer antigen, or a cell-binding factor.

13. The method according to claim 9 or 10, wherein said lymphocytes are collected from peripheral blood.

14. The method according to claim 9 or 10, wherein said lymphocytes are activated by an immunomodulator to enhance cancer cell killing activators.

15. A composition for use in immune therapy, said composition comprising anti-cancer lymphocytes obtained by:

incubating lymphocytes with cancer cells under conditions to amplify mainly NK cells, non-MHC-bound T cells, or MHC-bound killer T cells,

wherein said amplified killer T cells are killer T cells specific to a cancer antigen.

16. The composition according to claim 15, wherein a class-I positive cancer cell is present.

C 17. The composition of claim 15 or 16, wherein said cancer cells are deficient for or have lower levels of class I antigen expression.

18. The composition of claim 15 or 16, wherein said cancer cells express B7, or a combination of B7 and a cancer antigen, or a cell-binding factor.

19. The composition of claim 15 or 16, wherein said lymphocytes are collected from peripheral blood.

20. The composition of claim 15 or 16, wherein said lymphocytes are activated by an immunomodulator to enhance cancer cell killing activators.--